IDH Mutation of Pan-Cancer
The prevalence of IDH1/IDH2 mutations in 28.868 patients with different cancer types is summarized in Figure 1 , with biliary tract cancer patients having the highest levels of IDH1/IDH2mutations (80/1377). Across all 28,868 patients, the mutational frequencies of IDH1 and IDH2 were 0.81% and 0.47%, respectively.
We further investigated the genetic variation profile of IDHmutated patients (Figure 2). Targeted therapies have been successfully developed to treat lung cancer harboring driver gene mutations. In lung cancer, driver gene mutations EGFR and KRAS were the most significantly mutated genes, whereas TP53 , PBRM1 andBAP1 were more frequently observed in biliary tract cancer (Fig. 2A, C ). In addition, TP53 , PBRM1 andBAP1 were high frequency mutated gene in liver cancer (Fig. 2B ). APC , TP53 and KRAS were among the top mutated genes in colorectal cancer, while TP53 .SPTA1 and ACVR2A were more in IDH mutated gastric cancer (Fig. 2D,E).